Literature DB >> 19846211

Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery?

A Fagotti1, F Fanfani, G Vizzielli, V Gallotta, A Ercoli, A Paglia, B Costantini, M Vigliotta, G Scambia, G Ferrandina.   

Abstract

OBJECTIVES: Primary: To investigate whether S-LPS could contribute to a better identification of patients to submit to IDS. Secondary: To identify the most appropriate level of laparoscopic index value (PIV) to identify inoperable patients in this subset of patients.
METHODS: A prospective single-institutional study including patients with advanced ovarian/peritoneal cancer (FIGO stage IIIC-IV) to be submitted to IDS after NACT. Patients have been considered eligible for surgical exploration in case of complete/partial radiological or serological response; stable disease if primary surgery had been performed in a different hospital; progressive radiological disease in the presence of serological response, young age, and good performance status (ECOG <1); and progressive serological disease with stable clinical and radiological disease. A laparoscopic assessment for each patient has been performed.
RESULTS: Ninety-eight consecutive AOC patients submitted to NACT have been eligible for the study. With the addition of S-LPS to the RECIST criteria, a surgical exploration is performed in all patients and the percentage of explorative laparotomies drops to about 10%. The use of S-LPS after the GCIG criteria can reduce the risk of both explorative laparotomies from 30% to 13%, and inappropriate unexplorations from 18% to 0%. Moreover, at a PIV >4 the probability of optimally resecting the disease at laparotomy is equal to 0.
CONCLUSIONS: Present data suggest that S-LPS can play a relevant role to discriminate patients with partially/stable disease or referred from other Institutions after NACT, which can be susceptible of successful IDS.

Entities:  

Mesh:

Year:  2009        PMID: 19846211     DOI: 10.1016/j.ygyno.2009.09.015

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  13 in total

1.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

Review 2.  Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care.

Authors:  Natalia Rodriguez Gómez-Hidalgo; Bertha Alejandra Martinez-Cannon; Alpa M Nick; Karen H Lu; Anil K Sood; Robert L Coleman; Pedro T Ramirez
Journal:  Gynecol Oncol       Date:  2015-03-28       Impact factor: 5.482

3.  Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience.

Authors:  Valerio Gallotta; Anna Fagotti; Francesco Fanfani; Gabriella Ferrandina; Camilla Nero; Barbara Costantini; Salvatore Gueli Alletti; Vito Chiantera; Alfredo Ercoli; Giovanni Scambia
Journal:  Surg Endosc       Date:  2014-01-11       Impact factor: 4.584

Review 4.  Current Recommendations for Minimally Invasive Surgical Staging in Ovarian Cancer.

Authors:  Anna Fagotti; Federica Perelli; Luigi Pedone; Giovanni Scambia
Journal:  Curr Treat Options Oncol       Date:  2016-01

5.  Accuracy of radiologic- laparoscopic peritoneal carcinomatosis categorization in the prediction of surgical outcome.

Authors:  Shimaa Abdalla Ahmed; Hisham Abou-Taleb; Noha Ali; Dalia M Badary
Journal:  Br J Radiol       Date:  2019-05-24       Impact factor: 3.039

Review 6.  The role of surgery in advanced epithelial ovarian cancer.

Authors:  María Martín-Cameán; Elsa Delgado-Sánchez; Antonio Piñera; Maria Dolores Diestro; Javier De Santiago; Ignacio Zapardiel
Journal:  Ecancermedicalscience       Date:  2016-08-17

7.  Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells.

Authors:  Daniela Catanzaro; Silvia Nicolosi; Veronica Cocetta; Marika Salvalaio; Andrea Pagetta; Eugenio Ragazzi; Monica Montopoli; Gianfranco Pasut
Journal:  Oncotarget       Date:  2018-03-30

8.  A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.

Authors:  Eleonora Ghisoni; Dionyssios Katsaros; Furio Maggiorotto; Massimo Aglietta; Marco Vaira; Michele De Simone; Gloria Mittica; Gaia Giannone; Manuela Robella; Sofia Genta; Fabiola Lucchino; Francesco Marocco; Fulvio Borella; Giorgio Valabrega; Riccardo Ponzone
Journal:  J Ovarian Res       Date:  2018-05-30       Impact factor: 4.234

9.  Preoperative colonoscopy in patients with a supposed primary ovarian cancer.

Authors:  Renata Raś; Edyta Barnaś; Joanna Skręt- Magierło; Anna Drozdzowska; Ewelina Bartosiewicz; Marek Sobolewski; Andrzej Skręt; Krzysztof Gutkowski
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

10.  Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer.

Authors:  Kazuto Nakamura; Yoshikazu Kitahara; Toshio Nishimura; Soichi Yamashita; Keiko Kigure; Ikuro Ito; Tatsuya Kanuma
Journal:  World J Surg Oncol       Date:  2020-08-13       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.